ProMIS Neurosciences, Inc.
NASDAQ: PMN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Neil K. Warma
- Employees
- 7
- Headquarters
- Toronto, Canada
- IPO year
- 2007
- Market cap
- $13.4M
- Website
- https://www.promisneurosciences.com
Loading PMN…
Loading profile data…Frequently asked questions about PMN
What does ProMIS Neurosciences, Inc. (PMN) do?
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its Pro...
Where does PMN trade?
ProMIS Neurosciences, Inc. (PMN) trades on the NASDAQ Capital Market.
What sector is PMN in?
ProMIS Neurosciences, Inc. (PMN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ProMIS Neurosciences, Inc.?
Neil K. Warma is the chief executive officer of ProMIS Neurosciences, Inc. (PMN).
Where is ProMIS Neurosciences, Inc. headquartered?
ProMIS Neurosciences, Inc. is headquartered in Canada.
Does PMN pay a dividend?
ProMIS Neurosciences, Inc. (PMN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PMN go public?
ProMIS Neurosciences, Inc. (PMN) completed its initial public offering in 2007.